This page contains a brief description that does not cover the medication. For more information read the review in Felleskatalogen.no for the respective drug.
Contents
Definition
- Infliximab is the active substance in Remicade, Remsima, Flixabi, Inflectra and Zessly and is one Biological drug which blocks TNF-alpha i immune system
- The treatment is intravenous in hospital, most often as day treatment. Active substance is infliximab
- Remicade, Remsima, Inflectra and Zessly er Bio-equivalent drugs all of which contain the active substance infliximab
Before start of treatment
- Medical examinations to rule out infections (Hepatitis B, Hepatitis C, Tuberkulosis (Tbc))
- Blood tests
- Urine
- X-ray or CT of lungs
- Tuberculosis screening: more here
Vaccines
- Consider annual flu vaccine
- Evaluate pneumococcal vaccine before starting treatment (effect lasts for 5-10 years)
- Consider hepatitis B vaccine before initiating treatment (exposed persons)
- "Live vaccines" should not be used
- More about vaccines here
Dosage
- Gives intravenously, every 6-8 week. Can also be dosed following body surface area: Calculator (based on Height and Weight)
- Common dosage at Rheumatoid arthritis (arthritis) in adults
- Starting dose 3 mg / kg, repeat 2 and 6 weeks after 1. Infusion, then every 8. week
- The dose may be increased if needed
- Combination with Methotrexate is common
Physician controls / follow-up
- Specialist / Specialist in Rheumatology and General Practitioner
Measurement of serum concentration
- Serum concentration and antibody measurement (Inflix simab, OUS on own requisition). Measured in blood before new dose is given (bottom concentration): For recommended reference range and supplemental information is recommended anx.no (infliksimab)
Patient information
- Link here (the Norwegian Medical Association)
- The Norwegian «Common Catalog»
- UpToDate (American side)
Medications, BINDEVEVSSYKDOMMER.no
This page has had 1 visits today